EXCLUSIVE: Co-Diagnostics Reaches Regulatory Milestone for PCR Respiratory Test Platform - Co-Diagnostics
Co-Diagnostics (NASDAQ:CODX) said it completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument. The company plans to include the results in its FDA submission package for a Dual 510(k) and CLIA Waiver by Application targeted for Q3 2026. Shares were down 0.65% premarket to $3.08.
How this was made
The 30-second read
Why it matters
By completing both analytical and clinical performance studies (including >10,000 cup runs and an external multicenter reproducibility study), the company advances a key regulatory gating item for its planned FDA filing in Q3 2026.
Market read
Traders may treat this as incremental de-risking toward an FDA filing timeline, but without an FDA outcome or new revenue numbers, it is more of a medium-horizon catalyst than an immediate re-pricing event.
What to watch
The article does not quantify study outcomes (e.g., sensitivity/specificity) or submission readiness beyond “planned submission package,” so investors may still need confirmation of final documentation and FDA interaction milestones.
Background
Co-Diagnostics is preparing an FDA submission for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test, including a Dual 510(k) and a CLIA Waiver by Application.
Ticker impact
Co-Diagnostics says it completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro, supporting a planned Dual 510(k) and CLIA Waiver submission to FDA in Q3 2026.
Near-term impact likely modest, but the update can support a gradual re-rating if investors view FDA filing readiness as de-risking.
The article provides specific validation-study completion details and a targeted FDA submission window (Q3 2026), but it does not include an FDA decision, approval, or new financial guidance.
Market effects
Highlights execution milestones in molecular diagnostics/IVD regulatory pathways (analytical+clinical validation for multiplex respiratory tests and CLIA waiver by application).
South Asia distribution expansion via CoSara could broaden revenue opportunity, though the article provides no near-term financial impact.
Supports broader preparedness for respiratory multiplex testing demand, but the news is primarily company-specific regulatory progress.
Counterpoint
Completion of studies does not guarantee FDA acceptance or waiver approval; delays or additional data requests could still push timelines beyond Q3 2026.
Key entities
- companyCo-Diagnostics Inc.
NASDAQ-listed molecular diagnostics company preparing FDA submission for its multiplex PCR respiratory test platform.
- productCo-Dx PCR Flu A/B & RSV upper respiratory multiplex test
Multiplex PCR test whose analytical and clinical performance studies were completed for FDA submission readiness.
- regulatorU.S. Food and Drug Administration (FDA)
Agency targeted for a Dual 510(k) and CLIA Waiver by Application submission in Q3 2026.
- partnerCoSara Diagnostics Pvt. Ltd
Distribution partner agreement expanded across South Asia (Bangladesh, Pakistan, Nepal, Sri Lanka).
